Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521391 | 0.95 | IKBKB (0.58) | IKBKBALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3519868 | 0.91 | IKBKB (0.68) | IKBKBLMNAMEN1KMT2ACDK2 | |
| SCHEMBL3520938 | 0.88 | GAA (0.58) | IKBKBALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3520047 | 0.87 | IKBKB (0.59) | IKBKBALDH1A1MEN1KMT2AGAA | |
| SCHEMBL3520101 | 0.86 | IKBKB (0.73) | IKBKBLMNACDK2CHUK | |
| SCHEMBL3520630 | 0.86 | IKBKB (0.70) | IKBKBLMNAMEN1KMT2ACDK2 | |
| SCHEMBL3522392 | 0.85 | IKBKB (0.70) | IKBKBMEN1KMT2ACDK2CHUK | |
| SCHEMBL3519790 | 0.84 | IKBKB (0.70) | IKBKBCDK2CHUK | |
| SCHEMBL3517815 | 0.84 | IKBKB (0.69) | IKBKBCDK2CHUK | |
| SCHEMBL3520259 | 0.84 | IKBKB (0.65) | IKBKBCDK2CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885ALDH1A1 1072/4885LMNA 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.